DelveInsight Business Research, LLP: Mild Cognitive Impairment Market is Predicted to Advance at a CAGR of 11.6% by 2034 | DelveInsight
According to DelveInsight's analysis, the mild cognitive impairment market is anticipated to increase during the forecast period (2024-2034), owing to the rise in the launch of emerging therapies ...
Mild Cognitive Impairment Market is Predicted to Advance at a CAGR of 11.6% by 2034 | DelveInsight
DelveInsight's Mild Cognitive Impairment Market Insights report includes a comprehensive understanding of current treatment ...
Biogen Inc. stock outperforms competitors despite losses on the day
This was the stock's second consecutive day of losses.
Has Jim Cramer Lost Faith in Biogen Inc. (BIIB)’s Struggles with Alzheimer’s and MS Challenges?
We recently published a list of Jim Cramer Discussed These 10 NASDAQ 100 Stocks Recently. In this article, we are going to ...
2024 Research Report: Global Celiac Disease Treatment Market Projected To Reach $2.24 Billion By 2035 With A CAGR Of 11.84%
About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top ...
Vir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in Cancer
Shares of the battered biotech Vir Biotechnology were up more than 70% on Wednesday, as the company reported its first ...
STAT17h
Scribe Therapeutics becomes latest CRISPR company to announce layoffs
Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...
Sanofi taps Alloy Therapeutics for CNS antisense drug development
As part of the agreement, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up ...
stocknews20h
3 Biotech Stocks Innovating the Future of Medicine
The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing ...